Table 2.

Details of published and ongoing randomized trials of local consolidative therapy in patients with oligometastatic non-small cell lung cancer.

Study	Year	Trial Type	Number of Patients	Control Treatment	Intervention Treatment	Primary Endpoint	Reported Outcomes	Notes
Gomez [2,3]	2016	RCT Phase II	74 [49] b	Maintenance treatment (can include observation)	LCT followed by maintenance treatment	PFS	Longer PFS in intervention group
Iyengar [27]	2018	RCT Phase II	29	Maintenance chemotherapy alone	Stereotactic ablative radiotherapy (SAbR) + maintenance chemotherapy	PFS	Longer PFS in intervention group
Northstar [39,42]	2018 a	RCT Phase II	143 c	Osimertinib alone	Osimertinib + surgery and/or radiation	PFS	Ongoing	EGFR-mutated cancers
Lonestar [41]	2017 a	RCT Phase III	360 c	Nivolumab and Ipilimumab	Nivolumab and ipilimumab + surgery and/or radiation	OS	Ongoing

^a Year in which accrual began for the currently ongoing trials. ^b 74 patients were enrolled in the trial; 49 were randomized to the two treatment arms. ^c Anticipated accrual. Abbreviations. RCT, randomized controlled trial; LCT, local consolidative therapy; PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor.